Finolex Cables, Wockhardt, Paytm: Top five Nifty500 stocks that outperformed index this week; check list
NiveshIQ
NSE: WOCKPHARMA · Healthcare
Wockhardt Ltd.
₹2,179.40▼ ₹41.20 (-1.86%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on WOCKPHARMA. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Wockhardt Ltd.
Wockhardt Limited is a leading Indian pharmaceutical and biotech company operating globally. Its core business revolves around manufacturing and trading pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company has a robust pipeline of innovative products, including ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for sepsis and pneumonia treatment. Wockhardt has reported a strong turnaround in Q1 FY27, with consolidated revenue rising to ₹929 crore and net profit to ₹107 crore. The company is poised for growth, with the US launch of Zaynich expected in Q1 2027 and Europe approval expected by year-end. Wockhardt's competitive position is strengthened by its diversified product portfolio and expanding global prese
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹2,798 Cr +5.50% | ₹3,012 Cr +7.60% | ₹3,373 Cr +12.00% |
| EBITDA Margin | 2.36% | 13.05% | 20.66% |
| Net Profit | -24.00% | -87.90% | ₹199.00 Cr -449.10% |
| EPS | ₹-31.42 | ₹-3.02 | ₹13.12 |
Annual figures in Indian Rupees (Crores). Source: BSE filings.
Recent News
Finolex Cables, Wockhardt, Paytm: Top five Nifty500 stocks that outperformed index this week; check list
Wockhardt Ltd up for five straight sessions
🔒
+ 3 more stories about Wockhardt Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹929 Cr, PAT ₹107 Cr, EPS ₹6.55, EBITDA margin 24.0%. Growth context: revenue QoQ -3.7%, PAT QoQ -34.8%.
Management's near-term growth strategy hinges on product launches, approvals, and therapy-mix improvement, with new prod...
FY26 (last completed FY): revenue ₹3, 373 Cr, PAT ₹199 Cr, EBITDA margin 20.7%, EPS ₹13.12. Year-on-year: revenue YoY +1...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantEverything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for WOCKPHARMA
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track WOCKPHARMA alongside your other holdings
Unlock full WOCKPHARMA research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Wockhardt Ltd.?
NiveshIQ detects active intelligence signals for Wockhardt Ltd. (WOCKPHARMA) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Wockhardt Ltd.?
Wockhardt Ltd. operates in the Healthcare sector with a market capitalisation of ₹2,616,936.5L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.